PLAU and prostate cancer: Similarly, in prostate cancer cell lines, PKD3 contributed to the composition of the secretome by regulating the secretion of MMP-927 and the expression of urokinase-type plasminogen activator (uPA),73 both factors involved in ECM remodeling.77